THERAGEN ETEX CO.,LTD. Logo

THERAGEN ETEX CO.,LTD.

A biotech firm offering gene analysis and developing personalized cancer drugs.

066700 | KO

Overview

Corporate Details

ISIN(s):
KR7066700006
LEI:
Country:
South Korea
Address:
경기도 안산시 단원구 산단로 68번길 58(초지동), 안산시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

THERAGEN ETEX CO., LTD. is a biotechnology and pharmaceutical company specializing in genome-based personalized and precision medicine. The company integrates two core capabilities: advanced gene analysis and pharmaceutical development. Its genomics division provides high-level genome sequencing and analysis services, having achieved milestones such as creating the world's first female and tiger genome maps. The pharmaceutical division operates international GMP-certified facilities to manufacture and supply medicines. It focuses on developing a new drug pipeline that includes incrementally modified drugs, orphan drugs, and novel anticancer treatments. A key candidate, Vactosertib, is currently undergoing clinical trials in Korea and the U.S. for various cancers. This synergistic approach positions the company at the forefront of personalized healthcare solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-07-30 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.3 KB
2025-07-30 00:00
Management Discussion and Analysis
영업실적등에대한전망(공정공시)
Korean 10.6 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.2 MB
2025-05-08 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.1 KB
2025-05-08 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.9 KB
2025-05-08 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.4 KB
2025-04-30 00:00
Regulatory News Service
소속부변경
Korean 3.6 KB
2025-04-22 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-04-18 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.6 KB
2025-04-10 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 94.8 KB
2025-03-27 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 19.8 KB
2025-03-24 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 40.7 KB
2025-03-21 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 99.7 KB
2025-03-21 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 97.7 KB

Automate Your Workflow. Get a real-time feed of all THERAGEN ETEX CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for THERAGEN ETEX CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for THERAGEN ETEX CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore
950210
Prestige Consumer Healthcare Inc. Logo
Develops and markets leading over-the-counter brands for personal healthcare and wellness.
United States of America
PBH
Processa Pharmaceuticals, Inc. Logo
Develops next-gen chemo and therapies for chronic and life-threatening diseases.
United States of America
PCSA
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea
296160
PROKIDNEY CORP. Logo
Develops cellular therapies to preserve kidney function for patients with advanced Chronic Kidney Disease.
United States of America
PROK
ProMIS Neurosciences Inc. Logo
Developing selective antibody therapies targeting toxic proteins in neurodegenerative diseases.
United States of America
PMN
Propanc Biopharma, Inc. Logo
Developing proenzyme therapies to prevent solid tumor recurrence and metastasis.
United States of America
PPCB
ProQR Therapeutics N.V. Logo
Biotech developing RNA-editing therapies for genetic disorders using the body's own enzymes.
United States of America
PRQR
Protagenic Therapeutics, Inc.\new Logo
Developing novel peptide drugs to treat stress-related neuropsychiatric & CNS disorders.
United States of America
PTIX
Protagonist Therapeutics, Inc Logo
Develops peptide therapeutics for blood disorders and inflammatory or immunomodulatory diseases.
United States of America
PTGX

Talk to a Data Expert

Have a question? We'll get back to you promptly.